Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen for ER-beta-positive triple-negative metastatic breast cancer
ACTRN12610000506099Phase 2Terminated
- Sponsor
- Breast Cancer Trials
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of tamoxifen in triple-negative breast cancer (TNBC) and breast cancer, sponsored by Breast Cancer Trials. Primary endpoint: Overall response rate. Started Mar 2011; status: terminated.
02
Drugs
tamoxifen
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on ACTRN12610000506099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000506099.